Private Advisor Group’s Sonoma Pharmaceuticals SNOA Stock Holding History

Private Advisor Group’s Portfolio SNOA Stock Details SNOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-7	Closed	-$1K	–	3144
2020 Q2	$1K	Buy	+7	New	+$841	﹤0.01%	3753

Other funds holding SNOA

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Private Advisor Group's SNOA Position: Q3 2020 in Review

Private Advisor Group sold out of Sonoma Pharmaceuticals (SNOA) in Q3 2020, closing a stake of 7 shares — an estimated $1K sold.

Private Advisor Group first reported a position in SNOA in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 18 funds tracked by Wall St. Rank hold SNOA as of Q3 2020.

Private Advisor Group reported no remaining Sonoma Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Private Advisor Group sold 7 Sonoma Pharmaceuticals shares in Q3 2020, an estimated $1K.
Private Advisor Group first reported a position in Sonoma Pharmaceuticals in Q2 2020 and held it in 1 quarter.
Private Advisor Group's Sonoma Pharmaceuticals position peaked at $1K in Q2 2020.
18 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.